New PET tracer aims to spot Parkinson's in the brain
NCT ID NCT07640555
First seen Jun 11, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-phase study tests a new radioactive tracer called [¹⁸F]MODAG-009, which is designed to stick to abnormal clumps of a protein called alpha-synuclein in the brain. These clumps are linked to Parkinson's disease and multiple system atrophy (MSA). About 13 people—including those with Parkinson's, MSA, and healthy volunteers—will receive one injection of the tracer and then have a PET scan. The main goal is to see if the tracer can clearly light up these protein clumps and to check that it is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute for Neurodegenerative Disorders and XingImaging, LLC
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[¹⁸F]MODAG-009 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could lead to a new way to diagnose Parkinson's disease and multiple system atrophy more accurately using brain scans.
What could go wrong
This is a very early, small study (13 people) focused on imaging, not treatment. The tracer may not clearly distinguish between conditions or could have safety issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.